DexCom, Inc.
DXCMMedical Devices
$82.29+2.95%As of Oct 30vs prior close
- Market cap
- $30.7B
- P/E (TTM)
- 31.9×
- P/E (FY1)
- 30.9×
- From 52W high
- −10.88%
- EPS (LTM)
- $2.54
- Revenue (LTM)
- $5.1B
- Net margin
- 19.41%
- Dividend yield
- 0.00%
Nomior Score
78
Vanguard CompounderTop 3% of the scored universe
Growth68
Quality76
Value54
Momentum81
Resilience56
Growth
+26.22%revenue a year over 9 fiscal years
FY16 $573.3MLTM $5.1B
Connections
Revenue to profitQ3 FY26
20% of revenue became net profit, down 3 pts on a year.
Latest resultsThird Quarter 2026
- Revenue
- $1.344 billion
- Net income
- $275.1 million
- Diluted EPS
- $0.72
- Adjusted EPS
- $0.73
Revenue grew strongly in the quarter, led by the United States, with international sales also rising. Gross margin and operating income improved faster than sales, while GAAP net income was broadly steady compared with the prior year. Management raised its full-year revenue and operating margin outlook and announced a new share repurchase authorization.
Who owns it
7funds